Oncosec Medical Inc (ONCS) 0.5301 $ONCS
OncoSec Medical Expands Legal Team, Appoints Sheela Mohan-Peterson as General Counsel and Corporate Secretary
Business Wire - Wed Sep 17, 5:02AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, has appointed Sheela Mohan-Peterson, J.D., M.S. to the position of General Counsel and Corporate Secretary. In this newly created role, she will be responsible for leading the Company's global legal strategy and guiding the continued expansion of its intellectual property portfolio. Ms. Mohan-Peterson will be supported by an experienced internal legal team that includes legal associate and paralegal positions.
OncoSec Medical Appoints Dr. Mai H. Le to Position of Chief Medical Officer and Names Dr. Robert H. Pierce as Chief Scientific Officer
Business Wire - Tue Sep 16, 5:02AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, has appointed Mai H. Le, M.D. to the position of Chief Medical Officer. In this role, Dr. Le will oversee worldwide clinical development and regulatory activities for OncoSec's intratumoral cancer immunotherapy programs. In addition, Robert Pierce, M.D., who previously served as Chief Medical Officer, has been named to the newly created position of Chief Scientific Officer and Global Head of R&D. Furthermore, Tu Diep, M.Sc., who has served as Executive Director, Clinical Development, will now assume the position of Vice President of Operations.
OncoSec Medical to Present Data at ESMO 2014 Congress
Business Wire - Tue Sep 09, 5:02AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will present data from ongoing clinical and pre-clinical studies at the European Society for Medical Oncology (ESMO) 2014 Congress, to be held September 26-30 in Madrid, Spain. OncoSec is proud to be presenting an abstract titled, "Immune correlates of intratumoral IL-12 electroporation", as part of a poster presentation taking place 12:45 PM - 1:45 PM CEST on Sunday, September 28th.
OTC Daily News Report
PR Newswire Europe - Wed Sep 03, 8:05AM CDT
LONDON, September 3, 2014 /PRNewswire/ --
OncoSec Medical to Present at Five Events in September
Business Wire - Tue Sep 02, 5:02AM CDT
OncoSec Medical Inc. (OTCQB:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will present at five events in September. The company's agenda includes a number of high-profile scientific and investment conferences.
OTC Daily Stock News: Apptigo International, Inc. Onco Sec Medical Inc., Monitise PLC, American Green, Inc. Terra Tech Corp, MusclePharm Corp
PR Newswire Europe - Thu Aug 07, 7:02AM CDT
LONDON, August 7, 2014 /PRNewswire/ --
OncoSec Medical names Dr Holbrook Kohrt to SAB
M2 - Wed Aug 06, 6:19AM CDT
Biopharmaceutical company OncoSec Medical (OTCQB:ONCS) disclosed on Wednesday that Dr Holbrook Kohrt, MD, PhD has been elected to its Scientific Advisory Board.
OncoSec Medical Appoints Dr. Holbrook Kohrt to Scientific Advisory Board
Business Wire - Wed Aug 06, 5:02AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based intratumoral cancer immunotherapy, has appointed Dr. Holbrook Kohrt, M.D., Ph.D., to the company's Scientific Advisory Board. Dr. Kohrt joins a growing panel of distinguished experts and renowned thought leaders, and will contribute his considerable expertise to the company as it works to advance an expanding immuno-oncology pipeline.
OncoSec Medical To Present at 2014 DNA Vaccine Conference
Business Wire - Thu Jul 17, 5:02AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based intratumoral cancer immunotherapy, announces that several company representatives will present at the International Society of DNA Vaccines (ISDV) 2014 DNA Vaccine Conference, being held July 21-23, 2014 at the Westin San Diego Gaslamp Quarter Hotel in San Diego, CA.
OncoSec Medical To Present at Bioelectrochemistry Gordon Research Conference on July 8 and July 10
Business Wire - Wed Jul 02, 5:02AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based intratumoral cancer immunotherapy, announces that Robert Pierce, M.D., Chief Medical Officer, and Richard Heller, Ph.D., Scientific Advisory Board member, will present at the Bioelectrochemistry Gordon Research Conference being held July 6-11, 2014 at the University of New England in Biddeford, ME.
OncoSec Medical Appoints Dr. Soldano Ferrone to Scientific Advisory Board
Business Wire - Wed Jun 25, 5:02AM CDT
OncoSec Medical Inc. (OTCQB:ONCS), a company developing its ImmunoPulse DNA-based intratumoral cancer immunotherapy, has appointed Dr. Soldano Ferrone, M.D., Ph.D., to the company's Scientific Advisory Board. Dr. Ferrone is an internationally renowned expert in tumor immunology, and will contribute his considerable expertise to the company as it works to advance an expanding intratumoral immunotherapy pipeline.
OncoSec Medical Announces YTD Results as of April 30, 2014
Business Wire - Fri Jun 13, 8:00AM CDT
OncoSec Medical Inc. (OTCQB:ONCS), a company developing its ImmunoPulse DNA-based immunotherapy to treat solid tumors, today announced financial results for the nine months ended April 30, 2014.
OncoSec Medical Issues Annual Letter To Shareholders
Business Wire - Thu Jun 12, 5:03AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based intratumoral cancer immunotherapy, today issued the following letter from Punit Dhillon, President and CEO, to the company's shareholders:
OncoSec Medical to Present at Two Conferences in New York City in April
Business Wire - Mon Mar 31, 5:03AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based immunotherapy to treat solid tumors, will present at the 13th Annual Needham Healthcare Conference and the HemOnc Today Melanoma and Cutaneous Malignancies Meeting in April.
PUNIT DHILLON of OncoSec Medical Incorporated (ONCS)-Other O bought Shares of ONCS
M2 - Fri Mar 21, 7:39AM CDT
Reported by InsiderCow.com at 2014-03-20 14:21:26 ET
OncoSec Medical to Present at 2nd Annual Sachs Cancer Bio Partnering & Investment Forum
Business Wire - Mon Mar 17, 5:03AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, today announced that Punit Dhillon, President and CEO, will present a corporate overview of the company at the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum at the New York Academy of Sciences on Wednesday, March 19th at 3:00 p.m. (EST).
OncoSec Medical to Evaluate Increased Dose Frequency of ImmunoPulse in Ongoing Phase II Melanoma Trial
Business Wire - Wed Mar 12, 5:02AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, announced today that the company has submitted a protocol addendum to the FDA and institutional IRBs to evaluate an increased dose frequency for ImmunoPulse in an expansion of its ongoing Phase II melanoma trial. The Company expects to enroll up to 21 patients in this expansion, and expects two additional key cancer centers as sites participating in this study.
OncoSec Medical to Present at 24th Annual Wall Street Analyst Forum Institutional Investor Conference
Business Wire - Tue Feb 25, 5:02AM CST
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, today announced that Punit Dhillon, President and CEO, will present a corporate overview of the company at the 24th Annual Wall Street Analyst Forum Institutional Investor Conference at the University Club in New York, New York on Monday, March 3rd at 12:05 p.m. (EST).
OncoSec Medical Expands Legal Team, Appoints Sheela Mohan-Peterson as General Counsel and Corporate Secretary
Business Wire - Wed Sep 17, 5:02AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, has appointed Sheela Mohan-Peterson, J.D., M.S. to the position of General Counsel and Corporate Secretary. In this newly created role, she will be responsible for leading the Company's global legal strategy and guiding the continued expansion of its intellectual property portfolio. Ms. Mohan-Peterson will be supported by an experienced internal legal team that includes legal associate and paralegal positions.
OncoSec Medical Appoints Dr. Mai H. Le to Position of Chief Medical Officer and Names Dr. Robert H. Pierce as Chief Scientific Officer
Business Wire - Tue Sep 16, 5:02AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, has appointed Mai H. Le, M.D. to the position of Chief Medical Officer. In this role, Dr. Le will oversee worldwide clinical development and regulatory activities for OncoSec's intratumoral cancer immunotherapy programs. In addition, Robert Pierce, M.D., who previously served as Chief Medical Officer, has been named to the newly created position of Chief Scientific Officer and Global Head of R&D. Furthermore, Tu Diep, M.Sc., who has served as Executive Director, Clinical Development, will now assume the position of Vice President of Operations.
OncoSec Medical to Present Data at ESMO 2014 Congress
Business Wire - Tue Sep 09, 5:02AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will present data from ongoing clinical and pre-clinical studies at the European Society for Medical Oncology (ESMO) 2014 Congress, to be held September 26-30 in Madrid, Spain. OncoSec is proud to be presenting an abstract titled, "Immune correlates of intratumoral IL-12 electroporation", as part of a poster presentation taking place 12:45 PM - 1:45 PM CEST on Sunday, September 28th.
OTC Daily News Report
PR Newswire Europe - Wed Sep 03, 8:05AM CDT
LONDON, September 3, 2014 /PRNewswire/ --
OncoSec Medical to Present at Five Events in September
Business Wire - Tue Sep 02, 5:02AM CDT
OncoSec Medical Inc. (OTCQB:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will present at five events in September. The company's agenda includes a number of high-profile scientific and investment conferences.
OTC Daily Stock News: Apptigo International, Inc. Onco Sec Medical Inc., Monitise PLC, American Green, Inc. Terra Tech Corp, MusclePharm Corp
PR Newswire Europe - Thu Aug 07, 7:02AM CDT
LONDON, August 7, 2014 /PRNewswire/ --
OncoSec Medical names Dr Holbrook Kohrt to SAB
M2 - Wed Aug 06, 6:19AM CDT
Biopharmaceutical company OncoSec Medical (OTCQB:ONCS) disclosed on Wednesday that Dr Holbrook Kohrt, MD, PhD has been elected to its Scientific Advisory Board.
OncoSec Medical Appoints Dr. Holbrook Kohrt to Scientific Advisory Board
Business Wire - Wed Aug 06, 5:02AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based intratumoral cancer immunotherapy, has appointed Dr. Holbrook Kohrt, M.D., Ph.D., to the company's Scientific Advisory Board. Dr. Kohrt joins a growing panel of distinguished experts and renowned thought leaders, and will contribute his considerable expertise to the company as it works to advance an expanding immuno-oncology pipeline.
OncoSec Medical To Present at 2014 DNA Vaccine Conference
Business Wire - Thu Jul 17, 5:02AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based intratumoral cancer immunotherapy, announces that several company representatives will present at the International Society of DNA Vaccines (ISDV) 2014 DNA Vaccine Conference, being held July 21-23, 2014 at the Westin San Diego Gaslamp Quarter Hotel in San Diego, CA.
OncoSec Medical To Present at Bioelectrochemistry Gordon Research Conference on July 8 and July 10
Business Wire - Wed Jul 02, 5:02AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based intratumoral cancer immunotherapy, announces that Robert Pierce, M.D., Chief Medical Officer, and Richard Heller, Ph.D., Scientific Advisory Board member, will present at the Bioelectrochemistry Gordon Research Conference being held July 6-11, 2014 at the University of New England in Biddeford, ME.
OncoSec Medical Appoints Dr. Soldano Ferrone to Scientific Advisory Board
Business Wire - Wed Jun 25, 5:02AM CDT
OncoSec Medical Inc. (OTCQB:ONCS), a company developing its ImmunoPulse DNA-based intratumoral cancer immunotherapy, has appointed Dr. Soldano Ferrone, M.D., Ph.D., to the company's Scientific Advisory Board. Dr. Ferrone is an internationally renowned expert in tumor immunology, and will contribute his considerable expertise to the company as it works to advance an expanding intratumoral immunotherapy pipeline.
OncoSec Medical Announces YTD Results as of April 30, 2014
Business Wire - Fri Jun 13, 8:00AM CDT
OncoSec Medical Inc. (OTCQB:ONCS), a company developing its ImmunoPulse DNA-based immunotherapy to treat solid tumors, today announced financial results for the nine months ended April 30, 2014.
OncoSec Medical Issues Annual Letter To Shareholders
Business Wire - Thu Jun 12, 5:03AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based intratumoral cancer immunotherapy, today issued the following letter from Punit Dhillon, President and CEO, to the company's shareholders:
OncoSec Medical to Present at Two Conferences in New York City in April
Business Wire - Mon Mar 31, 5:03AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based immunotherapy to treat solid tumors, will present at the 13th Annual Needham Healthcare Conference and the HemOnc Today Melanoma and Cutaneous Malignancies Meeting in April.
PUNIT DHILLON of OncoSec Medical Incorporated (ONCS)-Other O bought Shares of ONCS
M2 - Fri Mar 21, 7:39AM CDT
Reported by InsiderCow.com at 2014-03-20 14:21:26 ET
OncoSec Medical to Present at 2nd Annual Sachs Cancer Bio Partnering & Investment Forum
Business Wire - Mon Mar 17, 5:03AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, today announced that Punit Dhillon, President and CEO, will present a corporate overview of the company at the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum at the New York Academy of Sciences on Wednesday, March 19th at 3:00 p.m. (EST).
OncoSec Medical to Evaluate Increased Dose Frequency of ImmunoPulse in Ongoing Phase II Melanoma Trial
Business Wire - Wed Mar 12, 5:02AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, announced today that the company has submitted a protocol addendum to the FDA and institutional IRBs to evaluate an increased dose frequency for ImmunoPulse in an expansion of its ongoing Phase II melanoma trial. The Company expects to enroll up to 21 patients in this expansion, and expects two additional key cancer centers as sites participating in this study.
OncoSec Medical to Present at 24th Annual Wall Street Analyst Forum Institutional Investor Conference
Business Wire - Tue Feb 25, 5:02AM CST
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, today announced that Punit Dhillon, President and CEO, will present a corporate overview of the company at the 24th Annual Wall Street Analyst Forum Institutional Investor Conference at the University Club in New York, New York on Monday, March 3rd at 12:05 p.m. (EST).
